Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Trevi Therapeutics Inc (TRVI)

Trevi Therapeutics Inc (TRVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 225,035
  • Shares Outstanding, K 72,592
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,070 K
  • EBIT $ -43 M
  • EBITDA $ -43 M
  • 60-Month Beta 1.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.21

Options Overview Details

View History
  • Implied Volatility 795.65% ( +693.66%)
  • Historical Volatility 60.28%
  • IV Percentile 99%
  • IV Rank 100.00%
  • IV High 795.65% on 11/07/24
  • IV Low 3.87% on 03/13/24
  • Put/Call Vol Ratio 196.50
  • Today's Volume 395
  • Volume Avg (30-Day) 122
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 3,900
  • Open Int (30-Day) 3,063

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.12
  • Number of Estimates 6
  • High Estimate -0.08
  • Low Estimate -0.14
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.80 +3.57%
on 11/07/24
3.44 -15.70%
on 10/21/24
+0.02 (+0.69%)
since 10/07/24
3-Month
2.58 +12.40%
on 08/14/24
3.69 -21.41%
on 09/17/24
+0.31 (+11.97%)
since 08/07/24
52-Week
0.97 +198.97%
on 11/27/23
4.00 -27.50%
on 03/21/24
+1.38 (+90.16%)
since 11/07/23

Most Recent Stories

More News
2 Breakout Growth Stocks With 200% Upside Potential

The success of their pipelines could change the narrative for these emerging biotech companies.

ANRO : 3.85 (-2.53%)
TRVI : 2.90 (-6.45%)
$SPX : 5,973.10 (+0.74%)
5 Biotech Stocks Under $10 With Multibagger Potential

As the biotech industry continues to redefine the healthcare landscape, here are five penny biotech stocks poised for meteoric growth in this evolving industry.

ADCT : 2.93 (-8.44%)
$SPX : 5,973.10 (+0.74%)
RZLT : 5.72 (-1.55%)
TRVI : 2.90 (-6.45%)
ELEV : 0.5771 (+4.93%)
CRDL : 2.0700 (+7.25%)
Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvioâ„¢ in Prurigo Nodularis

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral...

TRVI : 2.90 (-6.45%)
Trevi Therapeutics to Participate in Upcoming September Events

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral...

TRVI : 2.90 (-6.45%)
Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral...

TRVI : 2.90 (-6.45%)
Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral...

TRVI : 2.90 (-6.45%)
Trevi Therapeutics to Participate in Upcoming August Events

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral...

TRVI : 2.90 (-6.45%)
Trevi Therapeutics to Participate in Upcoming July Investor Events

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral...

TRVI : 2.90 (-6.45%)
Trevi Therapeutics to Participate in Upcoming June Conferences

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral...

TRVI : 2.90 (-6.45%)
Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral...

TRVI : 2.90 (-6.45%)

Business Summary

Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in...

See More

Key Turning Points

3rd Resistance Point 3.51
2nd Resistance Point 3.35
1st Resistance Point 3.12
Last Price 2.90
1st Support Level 2.74
2nd Support Level 2.58
3rd Support Level 2.35

See More

52-Week High 4.00
Last Price 2.90
Fibonacci 61.8% 2.84
Fibonacci 50% 2.49
Fibonacci 38.2% 2.13
52-Week Low 0.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar